更新于：2024-12-24
Atosiban acetate
醋酸阿托西班
更新于：2024-12-24
概要
基本信息
药物类型 合成多肽 |
别名 Antocile、Antocin、Antocin II + [21] |
作用机制 AVPR拮抗剂(血管加压素受体家族拮抗剂)、OXTR拮抗剂(催产素受体拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2000-01-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C43H67N11O12S2.C2H4O2 |
InChIKeySVDWBHHCPXTODI-QIWYXCRTSA-N |
CAS号914453-95-5 |
序列信息
Sequence Code 15073107
关联
34
项与 醋酸阿托西班 相关的临床试验A Randomized controlled trial to evaluate the efficacy of Atosiban in patients undergoing Embryo transfer. - NIL
Atosiban as a potential treatment for endometriosis - ENDOBAN pilot-study
The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain
100 项与 醋酸阿托西班 相关的临床结果
登录后查看更多信息
100 项与 醋酸阿托西班 相关的转化医学
登录后查看更多信息
100 项与 醋酸阿托西班 相关的专利（医药）
登录后查看更多信息
500
项与 醋酸阿托西班 相关的文献（医药）2025-02-01NEUROCHEMICAL RESEARCH
Oxytocin Protects Against Corticosterone-Induced DA Dysfunction: An Involvement of the PKA/CREB Pathway
Article
作者: Sookkua, Tichaporn ; Chaipunko, Sirinun ; Nopparat, Chutikorn ; Chutabhakdikul, Nuanchan
Abstract:
Chronic stress disrupts dopamine (DA) transmission, adversely affecting mood and contribution to neuropsychiatric disorders like ADHD, autism, schizophrenia, anxiety, depression, and drug addiction. The neuropeptide oxytocin (OXT) plays a key role in social cognition, bonding, attachment, and parenting behaviors. In addition, OXT can modulate the activity of the HPA axis, counteracting the effects of stress, and alleviating fear and anxiety. However, whether OXT can mitigate stress-induced DA dysfunction and the underlying mechanisms remains unclear. This study investigated the neuroprotective effects of OXT on corticosterone (CORT) induced DA dysfunction in the neuroblastoma cell line SH-SY5Y. The results revealed that CORT decreases the levels of intracellular signaling molecules associated with DA function, including phosphorylated tyrosine hydroxylase (pTH), phosphorylated cAMP response element-binding protein (pCREB), and protein kinase A (PKA). Interestingly, pretreatment with OXT mitigated CORT-induced DA dysfunction through its potent PKA activator properties. In addition, the neuroprotective effect of OXT was abolished by atosiban (an OXT receptor antagonist) or H89 (a PKA inhibitor). Our results suggest that OXT protects dopaminergic neuroblastoma cells from CORT-induced DA dysfunction, potentially through the involvement of oxytocin receptors and the PKA/CREB signaling pathway. These findings contribute to the understanding of the neurobiological mechanisms underlying stress resilience and highlight potential pathways for developing targeted treatments that leverage the neuroprotective properties of OXT to address disorders characterized by DA dysregulation and impaired stress responses.
2024-12-01MEDICINA CLINICA
Drug-induced hyponatraemia and possible related signals: Analysis of 659 cases reported to the Spanish Pharmacovigilance System and disproportionality analysis
Article
作者: Sainz-Gil, María ; Estévez Asensio, Lucía ; Fernández-Araque, Ana M. ; Verde Rello, Zoraida ; Velasco-González, Verónica ; Fernández-Araque, Ana M ; García, Montserrat
INTRODUCTION:
Hyponatraemia has negative effects on cognitive function and gait stability and is a risk factor for osteoporosis, falls, fractures and hospital mortality. Acute hyponatraemia can lead to neurological dysfunction due to cerebral oedema. Its rapid correction can also be fatal, leading to osmotic demyelination syndrome. For some antiepileptics, thiazides, benzodiazepines or antidepressants this reaction is widely described. Knowing which drugs are most likely to cause hyponatraemia will allow early detection and prevention of its complications, as well as individualising the prescription of these drugs according to the patient's characteristics.
OBJECTIVE:
The main objectives are to identify potential new safety signals related to hyponatraemia and to analyse the cases of hyponatraemia reported to the Spanish Pharmacovigilance System for Medicines for Human Use (SEFV-H).
METHOD:
A disproportionality and a descriptive analysis of individual case safety reports (ICSR) was performed in the SEFV-H database (FEDRA).
RESULTS:
Six hundred and fifty-nine cases of suspected drug-induced hyponatraemia were found (0.6% of the total database). Over the 5 years period studied, there was a 57% increase in the number of hyponatraemia reports in Spain. Most of the reported cases were serious (93%). Patients were most often women (63.7%) and elderly (71.9%). The time to onset ranged from 1 to 7030 days (median, 79 days) and approximately 70% of the total occurred within the first year of treatment. Five hundred and forty-six patients (82.9%) showed complete recovery after the withdrawal of the suspected medicine. Diuretics (reported in 57.7% of the cases), antidepressants (in 25%), drugs acting on renin angiotensin system (in 24%) and antiepileptics (in 20.2%) were the most frequent involved drugs. Disproportionate reporting has been found for almost all the substances most frequently reported, higher for amiloride and oxcarbazepine. Regarding new safety signals, the Reporting Odds Ratio (ROR) (95% CI) was found to be statistically significant for valsartan [7.7 (5.1-11.5)], olmesartan [7.3 (4.7-11.1)], amlodipine [3.4 (2.1-5.4)], pregabalin [2.5 (1.4-4.5)], irbesartan [18.6 (9.6-35.9)], paliperidone [2.7 (1.3-5.7)], ritonavir [2.4 (1.1-5.5)], atosiban [29.7 (8.6-102.2)], melphalan [9.7 (3.5-26.8)] and clozapine [4.4 (1.6-11.8)]. These active ingredients do not include this reaction on their SPC and comply with the EMA criteria for a safety signals.
CONCLUSION:
There are increasing reports of drug-induced hyponatraemia. It can be serious and seems to most often affect women over 65 years of age who take more than 1 medication. The time to onset varies and can be very long, so patient monitoring should be continuous throughout treatment. Hydrochlorothiazide is the drug with the highest number of reported cases in our setting. In terms of disproportionate reporting, diuretics leads the list, followed by antiepileptics as oxcarbazepine and eslicarbazepine. Safety signals were found for several drugs, more plausibly for pregabalin and paliperidone, thus a possible association between these drugs and hyponatraemia/SIAD is identified. This signal must be further studied. Meanwhile healthcare professionals should pay attention to this possibility. The reporting of suspected ADRs is essential to understand the risks associated with medicines once they are on the market.
2024-12-01JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Integrating Bulk RNA and Single‐Cell RNA Sequencing Identifies and Validates Lactylation‐Related Signatures for Intervertebral Disc Degeneration
Article
作者: Li, Fudong ; Lin, Wenbo ; Shi, Yangyang ; Shi, Jiangang ; Sun, Jingchuan ; Wang, Jinyu ; Yan, Chen ; Han, Linhui ; Ji, Chenglong ; Sun, Kaiqiang
ABSTRACT:
Glycolysis‐related lactylation has gained wide attention for regulating various cellular functions and diseases. Nevertheless, its intricate involvement in intervertebral disc degeneration (IVDD) is not yet fully understood. In this study, we unrevealed the intricate association between elevated lactylation levels and the development of IVDD. Subsequently, we harvested the lactylation‐related genes (LRGs) and systematically analysed the expression levels of these genes to establish a gene signature related to IVDD through multiple bulk RNA sequencing data. Six hub LRGs were determined and closely associated with the increased severity of IVDD. Among the six genes, CBX3 was the most upregulated in both in vivo and in vitro experiments. Furthermore, molecular docking identified atosiban acetate as a specific inhibitor for CBX3, and inhibiting the expression of CBX3 using atosiban acetate significantly repressed the glycolysis activity and global lactylation level, thus alleviating the progression of IVDD. In conclusion, the lactylation correlates positively with IVDD and the LRG signature could be used as a biomarker for the effective clinical treatment of IVDD. CBX3 emerged as one of the key LRGs in IVDD, and atosiban acetate, as a specific inhibitor for CBX3, may be a promising therapeutic candidate for IVDD by affecting lactylation.
36
项与 醋酸阿托西班 相关的新闻（医药）2024-07-01
·信狐药迅
申请上市细胞疗法临床申请ASH会议
2024-06-24
·信狐药迅
2024-06-21
·同写意
财报带量采购核酸药物申请上市医药出海
100 项与 醋酸阿托西班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早产 | 欧盟 | 2000-01-20 | |
| 早产 | 冰岛 | 2000-01-20 | |
| 早产 | 列支敦士登 | 2000-01-20 | |
| 早产 | 挪威 | 2000-01-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 1型阵发性家族性心室颤动 | 临床2期 | 比利时 | 2007-11-01 | |
| 1型阵发性家族性心室颤动 | 临床2期 | 捷克 | 2007-11-01 | |
| 1型阵发性家族性心室颤动 | 临床2期 | 西班牙 | 2007-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 194 | 繭齋衊壓範繭鏇糧艱顧(衊選廠餘遞夢廠夢壓範) = 淵廠蓋鏇選醖願鑰齋簾 願艱蓋積壓廠網繭鏇夢 (衊壓膚鹹選艱築鑰襯觸 ) | - | 2022-08-19 | ||
Placebo | 繭齋衊壓範繭鏇糧艱顧(衊選廠餘遞夢廠夢壓範) = 鑰衊壓積壓鹽網艱廠築 願艱蓋積壓廠網繭鏇夢 (衊壓膚鹹選艱築鑰襯觸 ) | ||||||
N/A | 56 | 窪膚積鏇淵鹽積淵襯願(製鬱積顧鏇壓觸膚製壓) = 鑰鏇鬱鹹衊願構簾築淵 蓋齋獵淵艱鏇窪獵夢襯 (膚鏇製簾鏇鹹簾糧糧鹽 ) 更多 | - | 2018-01-01 | |||
临床1期 | - | 顧糧蓋獵遞齋獵鹹範製(鑰繭築製遞鬱齋鬱繭蓋) = 積艱襯衊齋壓餘壓鹽糧 簾積夢膚醖鹽蓋繭夢餘 (壓選餘範夢糧廠淵膚鏇 ) 更多 | - | 2016-08-01 | |||
(Control group) | 顧糧蓋獵遞齋獵鹹範製(鑰繭築製遞鬱齋鬱繭蓋) = 鹽網蓋醖鹹襯簾窪構簾 簾積夢膚醖鹽蓋繭夢餘 (壓選餘範夢糧廠淵膚鏇 ) 更多 | ||||||
临床4期 | 800 | 鹹願壓鹹簾網願網遞蓋(襯築淵願窪廠糧廠鬱範) = 遞獵鹽窪遞獵淵範獵膚 築餘襯壓鑰蓋繭窪鏇齋 (壓艱衊選鹹積選壓繭淵 ) | - | 2014-12-01 | |||
Placebo | 鹹願壓鹹簾網願網遞蓋(襯築淵願窪廠糧廠鬱範) = 蓋鏇獵窪積淵襯網淵壓 築餘襯壓鑰蓋繭窪鏇齋 (壓艱衊選鹹積選壓繭淵 ) | ||||||
临床1期 | - | 71 | 憲窪鑰獵簾鏇淵觸窪憲(築製顧鏇鹽糧繭積鏇積) = 壓憲鏇遞構艱繭衊繭艱 繭獵鏇醖壓繭廠願獵醖 (膚壓齋獵夢夢製醖遞廠 ) 更多 | - | 2012-09-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用